Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

TracyAnn Perry, Debomoy Lahiri, Kumar Sambamurti, Demao Chen, Mark P. Mattson, Josephine M. Egan, Nigel H. Greig

Research output: Contribution to journalArticle

252 Citations (Scopus)

Abstract

Glucagon-like peptide-1(7-36)-amide (GLP-1) is an endogenous insulinotropic peptide that is secreted from the gastrointestinal tract in response to food. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion and lowers blood glucose and food intake in patients with type 2 diabetes mellitus. GLP-1 receptors, which are coupled to the cyclic AMP second messenger pathway, are expressed throughout the brains of rodents and humans. It was recently reported that GLP-1 and exendin-4, a naturally occurring, more stable analogue of GLP-1 that binds at the GLP-1 receptor, possess neurotrophic properties and can protect neurons against glutamate-induced apoptosis. We report here that GLP-1 can reduce the levels of amyloid-β peptide (Aβ) in the brain in vivo and can reduce levels of amyloid precursor protein (APP) in cultured neuronal cells. Moreover, GLP-1 and exendin-4 protect cultured hippocampal neurons against death induced by Aβ and iron, an oxidative insult. Collectively, these data suggest that GLP-1 can modify APP processing and protect against oxidative injury, two actions that suggest a novel therapeutic target for intervention in Alzheimer's disease.

Original languageEnglish
Pages (from-to)603-612
Number of pages10
JournalJournal of Neuroscience Research
Volume72
Issue number5
DOIs
StatePublished - Jun 1 2003

Fingerprint

Glucagon-Like Peptide 1
Amyloid
Iron
Neurons
Amyloid beta-Protein Precursor
Islets of Langerhans
Brain
Second Messenger Systems
Cyclic AMP
Type 2 Diabetes Mellitus
Blood Glucose
Gastrointestinal Tract
peptide A
Glutamic Acid
Cultured Cells
Rodentia
Alzheimer Disease
Eating
Cell Proliferation
Insulin

Keywords

  • Alzheimer's disease
  • Apoptosis
  • NGF
  • Oxidative stress
  • PC12 cell

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. / Perry, TracyAnn; Lahiri, Debomoy; Sambamurti, Kumar; Chen, Demao; Mattson, Mark P.; Egan, Josephine M.; Greig, Nigel H.

In: Journal of Neuroscience Research, Vol. 72, No. 5, 01.06.2003, p. 603-612.

Research output: Contribution to journalArticle

Perry, TracyAnn ; Lahiri, Debomoy ; Sambamurti, Kumar ; Chen, Demao ; Mattson, Mark P. ; Egan, Josephine M. ; Greig, Nigel H. / Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. In: Journal of Neuroscience Research. 2003 ; Vol. 72, No. 5. pp. 603-612.
@article{f1a85800df3f48cd91458287b16ae5c9,
title = "Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron",
abstract = "Glucagon-like peptide-1(7-36)-amide (GLP-1) is an endogenous insulinotropic peptide that is secreted from the gastrointestinal tract in response to food. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion and lowers blood glucose and food intake in patients with type 2 diabetes mellitus. GLP-1 receptors, which are coupled to the cyclic AMP second messenger pathway, are expressed throughout the brains of rodents and humans. It was recently reported that GLP-1 and exendin-4, a naturally occurring, more stable analogue of GLP-1 that binds at the GLP-1 receptor, possess neurotrophic properties and can protect neurons against glutamate-induced apoptosis. We report here that GLP-1 can reduce the levels of amyloid-β peptide (Aβ) in the brain in vivo and can reduce levels of amyloid precursor protein (APP) in cultured neuronal cells. Moreover, GLP-1 and exendin-4 protect cultured hippocampal neurons against death induced by Aβ and iron, an oxidative insult. Collectively, these data suggest that GLP-1 can modify APP processing and protect against oxidative injury, two actions that suggest a novel therapeutic target for intervention in Alzheimer's disease.",
keywords = "Alzheimer's disease, Apoptosis, NGF, Oxidative stress, PC12 cell",
author = "TracyAnn Perry and Debomoy Lahiri and Kumar Sambamurti and Demao Chen and Mattson, {Mark P.} and Egan, {Josephine M.} and Greig, {Nigel H.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1002/jnr.10611",
language = "English",
volume = "72",
pages = "603--612",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

AU - Perry, TracyAnn

AU - Lahiri, Debomoy

AU - Sambamurti, Kumar

AU - Chen, Demao

AU - Mattson, Mark P.

AU - Egan, Josephine M.

AU - Greig, Nigel H.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Glucagon-like peptide-1(7-36)-amide (GLP-1) is an endogenous insulinotropic peptide that is secreted from the gastrointestinal tract in response to food. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion and lowers blood glucose and food intake in patients with type 2 diabetes mellitus. GLP-1 receptors, which are coupled to the cyclic AMP second messenger pathway, are expressed throughout the brains of rodents and humans. It was recently reported that GLP-1 and exendin-4, a naturally occurring, more stable analogue of GLP-1 that binds at the GLP-1 receptor, possess neurotrophic properties and can protect neurons against glutamate-induced apoptosis. We report here that GLP-1 can reduce the levels of amyloid-β peptide (Aβ) in the brain in vivo and can reduce levels of amyloid precursor protein (APP) in cultured neuronal cells. Moreover, GLP-1 and exendin-4 protect cultured hippocampal neurons against death induced by Aβ and iron, an oxidative insult. Collectively, these data suggest that GLP-1 can modify APP processing and protect against oxidative injury, two actions that suggest a novel therapeutic target for intervention in Alzheimer's disease.

AB - Glucagon-like peptide-1(7-36)-amide (GLP-1) is an endogenous insulinotropic peptide that is secreted from the gastrointestinal tract in response to food. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion and lowers blood glucose and food intake in patients with type 2 diabetes mellitus. GLP-1 receptors, which are coupled to the cyclic AMP second messenger pathway, are expressed throughout the brains of rodents and humans. It was recently reported that GLP-1 and exendin-4, a naturally occurring, more stable analogue of GLP-1 that binds at the GLP-1 receptor, possess neurotrophic properties and can protect neurons against glutamate-induced apoptosis. We report here that GLP-1 can reduce the levels of amyloid-β peptide (Aβ) in the brain in vivo and can reduce levels of amyloid precursor protein (APP) in cultured neuronal cells. Moreover, GLP-1 and exendin-4 protect cultured hippocampal neurons against death induced by Aβ and iron, an oxidative insult. Collectively, these data suggest that GLP-1 can modify APP processing and protect against oxidative injury, two actions that suggest a novel therapeutic target for intervention in Alzheimer's disease.

KW - Alzheimer's disease

KW - Apoptosis

KW - NGF

KW - Oxidative stress

KW - PC12 cell

UR - http://www.scopus.com/inward/record.url?scp=0038248960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038248960&partnerID=8YFLogxK

U2 - 10.1002/jnr.10611

DO - 10.1002/jnr.10611

M3 - Article

C2 - 12749025

AN - SCOPUS:0038248960

VL - 72

SP - 603

EP - 612

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 5

ER -